ArticleDrugs in R&D2014
C60 fullerene as synergistic agent in tumor-inhibitory Doxorubicin treatment.
Article in Drugs in R&D, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 79 citations in OpenAlex.
- DFT design of PORSC advances · 2026Article
- Molecular modelling of fullerene CScientific reports · 2024Article
- Development of photoactive biomaterial using modified fullerene nanoparticles.Frontiers in chemistry · 2024Article
- Emerging concepts in designing next-generation multifunctional nanomedicine for cancer treatment.Bioscience reports · 2022Review
- Fullerene nanoparticles for the treatment of ulcerative colitis.Science China. Life sciences · 2022Article
- The Impact of Fullerenes as Doxorubicin Nano-Transporters on Metallothionein and Superoxide Dismutase Status in MCF-10A Cells.Pharmaceutics · 2022Article
- To inquire the effects of different geometric electrodes on current characteristics of CJournal of molecular modeling · 2021Article
- Identification of potential descriptors of water-soluble fullerene derivatives responsible for antitumor effects on lung cancer cells via QSAR analysis.Computational and structural biotechnology journal · 2021Article
- Quantification of Synergistic Effects of Ceragenin CSA-131 Combined with Iron Oxide Magnetic Nanoparticles Against Cancer Cells.International journal of nanomedicine · 2020Article
- Water-Soluble Pristine COxidative medicine and cellular longevity · 2020Article
- CPharmaceutics · 2019Article
- Interactions of newly synthesized platinum nanoparticles with ICR-191 and their potential application.Scientific reports · 2019Article
- A Novel Nanoconjugate of Landomycin A with CCellular and molecular bioengineering · 2019Article
- Mechano-signalling, induced by fullerene CInternational journal of nanomedicine · 2019Article
- Effect of CInternational journal of obesity (2005) · 2018Article
- Nanoparticle-Mediated Combination Therapy: Two-in-One Approach for Cancer.International journal of molecular sciences · 2018Review
- Metallothionein and Superoxide Dismutase-Antioxidative Protein Status in Fullerene-Doxorubicin Delivery to MCF-7 Human Breast Cancer Cells.International journal of molecular sciences · 2018Article
- Scavenging of reactive oxygen and nitrogen species with nanomaterials.Nano research · 2018Article
- CNanoscale research letters · 2018Article
- CFrontiers in physiology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDoxorubicin (Dox) is one of the most potent anticancer drugs, but its successful use is hampered by high toxicity caused mainly by generation of reactive oxygen species. One approach to protect against Dox-dependent chemical insult is combined use of the cytostatic drug with antioxidants. C60 fullerene has a nanostructure with both antioxidant and antitumor potential and may be useful in modulating cell responses to Dox.
objectiveThe aim of this study was to estimate the antitumor effect and antioxidant enzyme activity of combined C60 fullerene and Dox (C60 + Dox) in the liver and heart of mice with Lewis lung carcinoma compared with Dox treatment alone.
methodsHighly stable pristine C60 fullerene aqueous colloid solution (concentration 1.0 mg/ml, average hydrodynamic diameter of nanoparticles 50 nm) was used in the study and characterized by means of atomic force microscopy (AFM). The in vivo investigation of C60-Dox action was performed via the standard methods of histological and enzyme activity analyses.
resultsDox (total dose 2.5 mg/kg) combined with C60 fullerene (total dose 25 mg/kg) in tumor-bearing animals resulted in tumor growth inhibition, prolongation of life, metastasis inhibition, and increased number of apoptotic tumor cells and was more effective than the corresponding course of Dox treatment alone. C60 fullerene demonstrated a protective effect against superoxide dismutase and glutathione peroxidase inhibition induced by Dox-dependent oxidative insult in the liver and heart.
conclusionCombined treatment with C60 + Dox is considered to be a promising approach for cancer chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.